Following U.S. Stocks were among the “Top Gainers” during Monday’s trade: Microvision, Inc (NASDAQ:MVIS), Alon USA Energy, Inc (NYSE:ALJ), Affymetrix, Inc (NASDAQ:AFFX), Akorn, Inc (NASDAQ:AKRX)
Their insights are depicted underneath:
Microvision, Inc (NASDAQ:MVIS)’s shares picked up 4.13%, and closed at $2.52.
Through BUSINESS WIRE, Microvision Inc. (MVIS), a leader in innovative ultra-miniature projection display technology, declared it has signed a multi-year license contract with its Fortune Global 100 partner for MicroVision PicoP® display technology. The license contract marks an important milestone in the ongoing relationship between the two companies that began in April 2013.
The license contract grants the Fortune Global 100 corporation a non-exclusive license to MicroVision PicoP display technology for use in display modules it manufactures and sells. As part of the contract, MicroVision anticipates to receive an $8 million up-front license fee later this month. In addition to the initial up-front license fee, MicroVision will also receive royalties for display modules sold by the Fortune Global 100 corporation. Further terms of the license contract are confidential for competitive reasons.
MicroVision is the creator of PicoP® display technology, an ultra-miniature laser projection solution for mobile consumer electronics, automotive head-up displays and other applications.
Alon USA Energy, Inc (NYSE:ALJ), raised 4.12%, and closed at $14.42.
Through PRNewswire, Alon USA Energy, Inc. (ALJ), declared results for the fourth quarter and year ended December 31, 2014. Net revenue accessible to stockholders for the fourth quarter of 2014 was $6.7 million, or $0.10 per share, contrast to net loss accessible to stockholders of $(14.0) million, or $(0.21) per share, for the same period last year. Not including special items, Alon recorded net loss accessible to stockholders of $(0.2) million, or $0.00 per share, for the fourth quarter of 2014, contrast to net loss accessible to stockholders of $(8.0) million, or $(0.12) per share, for the same period last year.
Net revenue accessible to stockholders for the full year 2014 was $38.5 million, or $0.56 per share, contrast to net revenue accessible to stockholders of $23.0 million, or $0.33 per share, for 2013. Not including special items, Alon recorded net revenue accessible to stockholders of $38.1 million, or $0.55 per share, for the full year 2014, contrast to net revenue accessible to stockholders of $34.5 million, or $0.51 per share, for 2013.
Paul Eisman, CEO and President, commented, “We are happy with our accomplishments during 2014. We achieved the second highest annual adjusted EBITDA in our corporation’s history, in spite of the major turnaround at the Big Spring refinery in the second quarter of 2014. We raised our regular dividend by 67% from $0.24 to $0.40 per annum and paid a special dividend of $0.21 per share. Furthermore, we invested in growth projects across our assets, the largest of which was the vacuum tower project at the Big Spring refinery. In addition to these accomplishments, we were also able to reduce debt net of cash by about $40 million.”
Alon USA Energy, Inc. operates as an independent refiner and marketer of petroleum products primarily in the South Central, Southwestern, and the Western regions of the United States.
Affymetrix, Inc (NASDAQ:AFFX) enhanced 4.06%, and closed at $12.29.The company holds the book value per share of 3.68, whereas cash per share is 1.07. Price to book value is estimated to be 3.34, while price to sale value is 2.63. Analysts mean recommendation for the stock is said to be 2.90 (where 1=Buy, 5=sale).
Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia.
Akorn, Inc (NASDAQ:AKRX), rose 4.03%, and closed at $51.84. The company has the market capitalization of $5.59B. The beta value of the stock is 0.33. On the other hand the stock’s volatility for the week is 5.65%, and for the month is 3.95%. The stock price to book value is $14.32, however price to sale value is $9.29. Analyst’s mean recommendation regarding this stock is 1.90. (where 1=Buy, 5=Sale).
Akorn, Inc. manufactures and markets diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally.
